FDA approves apixaban

FDA announced recently it approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. » Full article

Aspirin resistance rare

Pharmacological resistance to aspirin is rare. Researchers at the University of Pennsylvania in Philadelphia said they could not identify one case of true drug resistance, according to the study published online Dec. 4 in the journal Circulation. » Full article

Benzodiazepines risk

Benzodiazepines, which have been associated with an increased incidence of infections in the critically ill, also may increase the risk of community-acquired pneumonia and mortality following pneumonia, according to a recent report published in Thorax.
» Full article

Industry-sponsored studies

Industry-sponsored studies are more likely to report favorable findings on the sponsor's drug or device, according to a recent literature review. Healthcare professionals who rely on systematic reviews to aid decision-making should be aware of this industry influence on conclusions. » Full article

CONTINUING EDUCATION

New CPE Series: December activity available now

Welcome to the fourth activity of our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The December activity will cover insulin therapy for diabetes care management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

P&T community ponders economic goals of healthcare reform and pharmacy

Finally, the grueling election is over and healthcare reform is here to stay. The questions now are: What will happen? When and how will it occur? What effect will it have? And, more specifically, how will it affect those of us in the medication management or pharmacy practice? » Full article

Subscribe Now!

You must click here to continue receiving the Formulary News Capsule

• Stroke rises in younger patients

• Aspirin benefit for prostate cancer

• Vitamin D and critically ill kids

• CER studies

RESOURCES

Drug Watch

Latest Clinical News

SURVEY

In the midst of a major evolution in the healthcare industry, what is the most significant way in which formulary committee functions will need to evolve?

a) Greater focus on comparative effectiveness research as that data unfolds.

b) Broadened comparative review of both self-administered, as well as clinic/office-administered injectable therapies.

c) Enhanced incorporation of real-world safety and effectiveness data in review processes.

d) Modified formulary committee composition/review processes to reflect the deep pipeline of complex biologic therapies.

e) Greater demands placed upon industry to demonstrate superiority with new product introductions.

Respond here and see what your colleagues think too. Click here to see the results of our last survey.

What can Formulary do for you?

Take our super short survey TODAY! http://www.surveygizmo.com/s3/1050662/Formulary-Readers